Related Experiment Video
Updated: Aug 28, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Don't Forget the Bones: Incidence and Risk Factors of Metabolic Bone Disease in a Cohort of Preterm Infants
Michela Perrone1, Amanda Casirati2, Stefano Stagi3
1Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Insights
Metabolic bone disease of prematurity (MBD) affects preterm infants due to interrupted mineral deposition. Lower birth weight and prolonged parenteral nutrition are key risk factors for MBD in these vulnerable infants.
Area of Science:
- Neonatology
- Pediatric Endocrinology
- Bone Metabolism
Background:
- Metabolic bone disease of prematurity (MBD) is characterized by reduced bone mineral content in preterm infants.
- Preterm birth disrupts critical third-trimester calcium and phosphorus deposition, leading to inadequate bone mineralization.
- MBD can cause growth faltering and respiratory complications, despite advances in neonatal care.
Purpose of the Study:
- To evaluate the incidence of MBD in very-low-birth-weight infants (VLBWI).
- To identify risk factors associated with MBD in this cohort.
- To assess the predictive value of serum alkaline phosphatase (ALP) for MBD risk.
Main Methods:
- A cohort of 238 VLBWIs was enrolled.
- Infants were categorized into increased risk (G1) and standard risk (G2) groups based on serum ALP and phosphorus levels.
- Linear regression analysis was used to identify independent predictors of MBD risk.
Main Results:
- Infants in the increased risk group had lower gestational age and birth weight.
- Increased risk was associated with longer parenteral nutrition support and higher rates of bronchopulmonary dysplasia.
- Birth weight and parenteral nutrition were identified as independent predictors of increased MBD risk.
Conclusions:
- MBD remains a significant concern in VLBWIs, influenced by factors like birth weight and nutritional support.
- Early identification of at-risk infants through serum ALP screening can guide preventive strategies.
- Preventive measures are crucial to mitigate long-term bone structure alterations and growth impairments.
Abstract:
Metabolic bone disease of prematurity (MBD) is a condition of reduced bone mineral content (BMC) compared to that expected for gestational age (GA). Preterm birth interrupts the physiological process of calcium (Ca) and phosphorus (P) deposition that occurs mostly in the third trimester of pregnancy, leading to an inadequate bone mineralization during intrauterine life (IUL). After birth, an insufficient intake of Ca and P carries on this alteration, resulting in overt disease. If MBD is often a self-limited condition, in some cases it could hesitate the permanent alteration of bone structures with growth faltering and failure to wean off mechanical ventilation due to excessive chest wall compliance. Despite advances in neonatal intensive care, MBD is still frequent in preterm infants, with an incidence of 16−23% in very-low-birth-weight (VLBW, birth weight <1500 g) and 40−60% in extremely low-birth-weight (ELBW, birth weight <1000 g) infants. Several risk factors are associated with MBD (e.g., malabsorption syndrome, parenteral nutrition (PN), pulmonary bronchodysplasia (BPD), necrotizing enterocolitis (NEC), and some chronic medications). The aim of this study was to evaluate the rate of MBD in a cohort of VLBWI and the role of some risk factors. We enrolled 238 VLBWIs (107 male). 52 subjects were classified as increased risk (G1) and 186 as standard risk (G2) according to serum alkaline phosphatase (ALP) and phosphorus (P) levels. G1 subjects have lower GA (p < 0.01) and BW (p < 0.001). Moreover, they need longer PN support (p < 0.05) and invasive ventilation (p < 0.01). G1 presented a higher rate of BPD (p = 0.026). At linear regression analysis, BW and PN resulted as independent predictor of increased risk (p = 0.001, p = 0.040, respectively). Preventive strategies are fundamental to prevent chronic alteration in bone structures and to reduce the risk of short stature. Screening for MBD based on serum ALP could be helpful in clinical practice to identify subjects at increased risk.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Inborn Errors of Metabolism
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Bone Remodeling
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

